Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A randomized, double-blind, placebo-controlled study of AIMSPRO in Multiple Sclerosis
2006-006872-39Phase 2Completed
- Sponsor
- Daval International Ltd
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in overactive bladder (OAB) and secondary-progressive multiple sclerosis (SPMS) comparing AIMSPRO with Placebo (2 arms). Primary endpoint: Change in average voided volume. Started Jun 2007; status: completed.
02
Drugs
hyperimmune caprine serum against hiv lysate
03
Conditions
overactive bladder (OAB)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2006-006872-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006872-39.